Prognostic Re-evaluation of Antinuclear Antibodies in Childhood Immune Thrombocytopenia
TH Open · 17.09.2026 · 10 (CP)
DOI: 10.1055/a-2938-6571 ↗Kurz gefasst
Fachartikel in der Zeitschrift TH Open, erschienen am 17.09.2026. Verfasst von Zeinab Muse und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric CoagulationAstrid Lindgren Children's Hospital, Karolinska University HospitalStockholmStockholm CountySweden. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Landsteiner Foundation for Blood Transfusion Research, Studienstiftung des Deutschen Volkes.
Abstract (Originalsprache)
Background
In the autoimmune bleeding disorder childhood immune thrombocytopenia (ITP), antinuclear antibodies (ANA) have been suggested as potential biomarkers for predicting chronic ITP. Unfortunately, published evidence remains conflicting and testing is not currently recommended in clinical routine.
Aim
This study aimed to validate the prognostic association of ANA with chronic ITP in newly diagnosed childhood ITP.
Methods
Data from 176 children with newly diagnosed ITP and a platelet count ≤20 × 109/L enrolled in the Treatment With or Without IVIg in Kids with ITP (TIKI) randomized controlled trial were available. ANA testing was performed on sera obtained within 72 h of diagnosis, before immunomodulatory treatment. Children were followed for 12 months to assess chronic ITP development, intravenous immunoglobulin (IVIg) treatment response, and spontaneous recovery.
Results
ANA were detected in 36/176 (20%) children. Chronic ITP developed in 21/176 children; 4/36 (11%) of ANA-positive versus 17/140 (12%) of ANA-negative patients (OR 0.90; 95% CI: 0.25–2.65). No differences were observed in platelet counts, spontaneous recovery, or IVIg responses when comparing children with and without ANA. ANA provided no additional prognostic value beyond the Childhood ITP Recovery Score, a clinical prediction rule for recovery from ITP. ANA were not associated with anti-platelet antibodies by platelet immunofluorescence (PIFT) or monoclonal antibody-immobilization of platelet antigens (MAIPA).
Conclusion
ANA testing at the time of diagnosis was not helpful to predict chronic ITP, IVIg treatment responses, or spontaneous recovery among children with newly diagnosed ITP and a platelet count ≤20 × 109/L. Future studies may evaluate whether ANA testing may be of value when performed at a later point in time.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric CoagulationAstrid Lindgren Children's Hospital, Karolinska University HospitalStockholmStockholm CountySweden.
- Department ResearchSanquin Blood Supply FoundationAmsterdamNoord-HollandNetherlands.
- Landsteiner LaboratoryAmsterdam University Medical Center, University of AmsterdamAmsterdamNetherlands.
- Princess Maxima Center for Pediatric OncologyUtrechtNetherlands.
- Department of Pediatric HematologyUniversity Medical Centre UtrechtUtrechtNetherlands.
- PurSang DiagnosticsAmsterdamNoord-HollandNetherlands.
ORCID-Profile: David E Schmidt
Förderung
- Landsteiner Foundation for Blood Transfusion Research
- Studienstiftung des Deutschen Volkes
Zitieren
APA
Muse, Z., Schmidt, D. E., Heitink-Pollé, K. M. J., Porcelijn, L., Gelderman, K. A., Bruin, M. C. A., Van der Schoot, C. E., Vidarsson, G., De Haas, M., & Kapur, R. (2026). Prognostic Re-evaluation of Antinuclear Antibodies in Childhood Immune Thrombocytopenia. TH Open, 10(CP). https://doi.org/10.1055/a-2938-6571
Vancouver
Muse Z, Schmidt DE, Heitink-Pollé KMJ, Porcelijn L, Gelderman KA, Bruin MCA, et al. Prognostic Re-evaluation of Antinuclear Antibodies in Childhood Immune Thrombocytopenia. TH Open. 2026;10(CP). doi:10.1055/a-2938-6571
BibTeX
@article{Muse2026,
author = {Muse, Zeinab and Schmidt, David E and Heitink-Pollé, Katja M J and Porcelijn, Leendert and Gelderman, Kyra A and Bruin, Marrie C A and Van der Schoot, C Ellen and Vidarsson, Gestur and De Haas, Masja and Kapur, Rick},
title = {Prognostic Re-evaluation of Antinuclear Antibodies in Childhood Immune Thrombocytopenia},
journal = {TH Open},
year = {2026},
volume = {10},
number = {CP},
doi = {10.1055/a-2938-6571}
}
EUVIMED